These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26595980)

  • 1. Built for the road ahead.
    Mansour A
    Healthc Financ Manage; 2015 Oct; 69(10):76-81. PubMed ID: 26595980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prescription for change.
    Testoni M
    Healthc Financ Manage; 2015 Oct; 69(10):30, 32. PubMed ID: 26595972
    [No Abstract]   [Full Text] [Related]  

  • 3. HHS defends expanded 340B drug discounts.
    Lee J
    Mod Healthc; 2014 Jun; 44(24):9. PubMed ID: 25137989
    [No Abstract]   [Full Text] [Related]  

  • 4. PhRMA sues on 340B orphans.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):17. PubMed ID: 24340726
    [No Abstract]   [Full Text] [Related]  

  • 5. An estimated $84.9 billion in uncompensated care was provided in 2013; ACA payment cuts could challenge providers.
    Coughlin TA; Holahan J; Caswell K; McGrath M
    Health Aff (Millwood); 2014 May; 33(5):807-14. PubMed ID: 24799578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. For some hospitals, the ACA increases revenue.
    Rosenberg K
    Am J Nurs; 2014 Sep; 114(9):19. PubMed ID: 25166239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who benefits from drug discounts? Drugmakers, hospitals battle over indigent-care program.
    Lee J
    Mod Healthc; 2013 Jul; 43(28):8-9. PubMed ID: 24044228
    [No Abstract]   [Full Text] [Related]  

  • 8. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
    Zeta LM
    Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the Affordable Care Act's Financial Impact on Safety-Net Hospitals in States That Expanded Medicaid and Those That Did Not.
    Dobson A; DaVanzo JE; Haught R; Phap-Hoa L
    Issue Brief (Commonw Fund); 2017 Nov; 2017():1-10. PubMed ID: 29232088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-31. PubMed ID: 27116794
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
    [No Abstract]   [Full Text] [Related]  

  • 12. The Impact of the ACA's Medicaid Expansion on Hospitals' Uncompensated Care Burden and the Potential Effects of Repeal.
    Dranove D; Gartwaite C; Ody Ch
    Issue Brief (Commonw Fund); 2017 May; 12():1-9. PubMed ID: 28574233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceuticals: drug importation--2005. End of Year Issue Brief.
    Varma P; Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708457
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicaid payment for generic drugs: achieving savings and access.
    Peters CP
    Issue Brief George Wash Univ Natl Health Policy Forum; 2010 Sep; (839):1-16. PubMed ID: 20928958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protect the 340B drug program.
    Hart C
    Mod Healthc; 2014 Feb; 44(7):24. PubMed ID: 24660395
    [No Abstract]   [Full Text] [Related]  

  • 17. What's at stake in effort to diminish 340B program.
    Henkel B
    Mod Healthc; 2014 Sep; 44(39):34. PubMed ID: 25509599
    [No Abstract]   [Full Text] [Related]  

  • 18. Double whammy.
    Rice S
    Mod Healthc; 2014 Jun; Suppl():6-10, 12. PubMed ID: 25016890
    [No Abstract]   [Full Text] [Related]  

  • 19. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
    PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 340B program presents opportunities--and challenges.
    Keough CL; Webster SA
    Healthc Financ Manage; 2009 Nov; 63(11):42-4, 46, 48. PubMed ID: 19891397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.